Cardiol Therapeutics’ ARCHER Phase II Myocarditis Data Published in ESC Heart Failure
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Cardiol Therapeutics ( (TSE:CRDL) ) just unveiled an update.
Cardiol Therapeutics Inc., a late-stage life sciences company specializing in anti-inflammatory and anti-fibrotic therapies for heart disease, is advancing its lead oral small-molecule CardiolRx™ for pericarditis, myocarditis, and heart failure. The firm’s pipeline spans the MAVERIC program in recurrent pericarditis, which includes a completed Phase II pilot and an ongoing pivotal Phase III trial, alongside development of CRD-38, a novel subcutaneous formulation targeting inflammatory heart disease.
On February 10, 2026, Cardiol announced that results from its Phase II ARCHER study of CardiolRx™ in acute myocarditis were published in ESC Heart Failure, a journal of the European Society of Cardiology. The randomized, double-blind, placebo-controlled trial in 109 patients showed CardiolRx™ significantly reduced left ventricular mass versus placebo, improved left atrial remodelling, and demonstrated favorable trends in markers of myocardial inflammation, while being safe and well tolerated.
These findings are considered consistent with reduced myocardial edema and inflammatory burden, changes that are associated with better clinical outcomes in myocarditis. Cardiol said the biological signals seen in ARCHER are directly relevant to its ongoing Phase III MAVERIC trial in recurrent pericarditis, bolstering the scientific rationale for CardiolRx™ across the spectrum of inflammatory myopericardial syndromes and potentially strengthening the company’s position in inflammatory heart disease therapeutics.
The most recent analyst rating on (TSE:CRDL) stock is a Hold with a C$1.50 price target. To see the full list of analyst forecasts on Cardiol Therapeutics stock, see the TSE:CRDL Stock Forecast page.
Spark’s Take on TSE:CRDL Stock
According to Spark, TipRanks’ AI Analyst, TSE:CRDL is a Neutral.
The score is held down primarily by very weak financial performance (pre-revenue profile, large ongoing losses, and substantial cash burn with shrinking equity), which increases financing and dilution risk despite low debt. Technicals provide only a modest offset due to improving short-term momentum, while valuation remains unattractive because the company is loss-making and offers no dividend support.
To see Spark’s full report on TSE:CRDL stock, click here.
More about Cardiol Therapeutics
Cardiol Therapeutics Inc. is a late-stage life sciences company developing anti-inflammatory and anti-fibrotic therapies for heart disease, with a focus on conditions such as pericarditis, myocarditis, and heart failure. Its lead small-molecule candidate, CardiolRx™, targets inflammasome pathway activation, and the company is also advancing CRD-38, a subcutaneous formulation aimed at inflammatory heart disease, including heart failure.
Cardiol’s clinical pipeline includes the MAVERIC program evaluating CardiolRx™ in recurrent pericarditis, comprising a completed Phase II pilot study and an ongoing pivotal Phase III trial. The company’s ARCHER program has investigated CardiolRx™ in acute myocarditis, and Cardiol has secured U.S. FDA Orphan Drug Designation for CardiolRx™ in pericarditis, reinforcing its niche focus in inflammatory cardiac indications.
Average Trading Volume: 88,450
Technical Sentiment Signal: Sell
Current Market Cap: C$153M
For an in-depth examination of CRDL stock, go to TipRanks’ Overview page.
